You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

299 Results
Statistical Reports
Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...
Feb 2025
Guidelines and Advice
Status: In-Review
ID: 4-17
Version: 2
Jan 2018
Guidelines and Advice
Status: Current
ID: GL 8-12
Updated
Jan 2026
Guidelines and Advice
Status: Current
ID: 7-11
Version: 3
Mar 2022
Drug
Other Name(s): Voranigo™
Quick Link(s):
Drug Monograph
New
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Mar 2026
Guidelines and Advice
Status: Archived
ID: SCT 6
Feb 2016

Pages